Ludger is delighted to announce that the GlySign project has begun. GlySign is a research training network on glycomic clinical markers and assay development for Precision Medicine. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 722095
Ludger, whose Head Office, R&D, analytical services and production laboratories are located within the U.K Bioscience ‘golden triangle’ (Oxford-Cambridge-London) at the Culham Science Centre, are joined in the GlySign consortium by Genos and Leiden University Medical Center, and will shortly be recruiting two PhD students to be based here at Culham.
For more information please visit: http://www.glysign.eu/